Innovus Pharmaceuticals Inc. (fka INNV)

[John Kent]

From INNV CEO"

"So first, before I answer, I want to say thank you to Bill for his continuous emails and advise. When I joined the company in 2013, the company had zero revenue had no products on the market, they did not even have a pipeline. The company has done a reverse merger at that time or the shares were locked and the volume was close to zero shares. So, really the - whatever price was on the stock that was not actually a real price for the company. I came in 2015 and I put in $2.5 million amount of credit of my own personal money and built the pipeline, the partnership's, the sales and marketing platform, and did not take any salary for three years. In addition, and as the filings with the SEC show, I actually purchased shares on the open market on two occasions to support the stock in 2013 and 2015. So, there is no CEO of an OTC public company or the risk is on money and time as I did. And I’m happy I did because now we are a reputable company, with a real pipeline of 21 products on multiple markets. Real continuously growing revenues, real drugs and our pipeline, we have respectable large pharma partners and clear path to profitability and growth. Yes, the share price might be down, but again we look forward for the market to really understand the value of the products we have, where we’re going and appreciate over time"

https://seekingalpha.com/article/4098907-innovus-pharmaceuticals-innv-bassam-damaj-q2-2017-results-earnings-call-transcript?page=3